Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Airway

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,312 result(s) found for: Airway. Displaying page 66 of 66.
    «« First « Previous 58  59  60  61  62  63  64  65  66 
    EudraCT Number: 2019-004905-29 Sponsor Protocol Number: CCSJ117A12201C Start Date*: 2020-12-28
    Sponsor Name:Novartis Pharma AG
    Full Title: A 12-week, multicenter, randomized, double-blind, parallel-arm, placebo-controlled study to assess the efficacy and safety of CSJ117, when added to existing asthma therapy in patients ≥18 years of ...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) LV (Prematurely Ended) HU (Prematurely Ended) BE (Completed) PL (Prematurely Ended) BG (Prematurely Ended) FR (Completed) SK (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001549-13 Sponsor Protocol Number: GB39242 Start Date*: 2016-12-16
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO ASSESS THE EFFICACY AND SAFETY OF MSTT1041A IN PATIENTS WITH UNCONTROLLED SEVERE ASTHMA
    Medical condition: Uncontrolled Severe Asthma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10003560 Asthma NOS LLT
    19.0 100000004855 10015888 Extrinsic asthma LLT
    19.0 100000004855 10003561 Asthma, unspecified LLT
    19.0 100000004855 10001705 Allergic asthma LLT
    19.0 100000004855 10003554 Asthma aggravated LLT
    19.0 100000004855 10068393 Neutrophilic asthma LLT
    19.0 100000004855 10022847 Intrinsic asthma LLT
    19.0 100000004855 10074614 Nocturnal asthma LLT
    19.0 100000004855 10003638 Atopic asthma LLT
    19.0 100000004855 10068463 Paucigranulocytic asthma LLT
    19.0 100000004855 10009029 Chronic obstructive asthma (with obstructive pulmonary disease), w/o-ment of status asthmaticus LLT
    19.0 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-000212-25 Sponsor Protocol Number: CQAW039A2323 Start Date*: 2018-12-27
    Sponsor Name:Novartis Pharma AG
    Full Title: A 52-week, multicenter, randomized, double-blind, double-dummy, parallel-group, placebo-controlled study of fevipiprant once daily plus standard-of-care (SoC) for reduction of systemic corticostero...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) CZ (Completed) SK (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) FR (Completed) GR (Completed) BG (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003772-37 Sponsor Protocol Number: CTBM100C2302 Start Date*: 2006-01-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Randomized, Open-label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to TOBI® in Cystic Fibrosis Subjects
    Medical condition: Pulmonary pseudomonas aeruginosa infections in patients with cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    10011762
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Completed) HU (Completed) GR (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004543-57 Sponsor Protocol Number: D9618C00001 Start Date*: 2006-03-29
    Sponsor Name:AstraZeneca AB
    Full Title: A 6-month randomized, double-blind, parallel-group, multicentre, placebo-controlled Phase II study to compare anti-asthmatic effect and safety of esomeprazole (Nexium) 40 mg twice daily or 40 mg on...
    Medical condition: Moderate to severe asthma and symptoms of gastroesophageal reflux disease (GERD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) HU (Completed) IT (Completed) SK (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003078-15 Sponsor Protocol Number: D5180C00007 Start Date*: 2018-07-04
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asth...
    Medical condition: Severe uncontrolled Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002073-22 Sponsor Protocol Number: CQAW039A2322 Start Date*: 2018-12-13
    Sponsor Name:Novartis Pharma AG
    Full Title: A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of fevipiprant once daily plus standard-of-care (SoC) for assessment of the efficacy in reduction of nasal polyps s...
    Medical condition: Nasal polyposis in patients with concomitant asthma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10028756 Nasal polyps PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) CZ (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-003004-33 Sponsor Protocol Number: AR-DEX-22-01 Start Date*: 2023-04-26
    Sponsor Name:Areteia Therapeutics, Inc.
    Full Title: A randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe ...
    Medical condition: Severe Eosinophilic Asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10068462 Eosinophilic asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) PL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002483-40 Sponsor Protocol Number: D3741C00007 Start Date*: 2018-12-05
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2b Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi Centre Study to Assess Efficacy and Safety of Multiple Dose Levels of AZD7594 DPI Given Once Daily for twelve weeks, com...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10003560 Asthma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-003629-45 Sponsor Protocol Number: IOV-LUN-202 Start Date*: 2021-05-05
    Sponsor Name:Iovance Biotherapeutics, Inc.
    Full Title: A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN -145) in Patients with Metastatic Non-Small-Cell Lung Cancer
    Medical condition: Metastatic Non-Small-Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004917-26 Sponsor Protocol Number: PS-G202 Start Date*: 2016-11-08
    Sponsor Name:Parion Sciences, Incorporated
    Full Title: A Phase 2a, Two-part, Randomized, Double-blind, Placebo-controlled, Incomplete Block Crossover Study to Evaluate the Safety and Efficacy of VX-371 Solution for Inhalation With and Without Oral Ivac...
    Medical condition: Primary Ciliary Dyskinesia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10069713 Primary ciliary dyskinesia PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) NL (Completed) PL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004277-26 Sponsor Protocol Number: GS-US-205-0110 Start Date*: 2008-04-29
    Sponsor Name:Gilead Sciences Inc
    Full Title: An Open-Label, Randomized, Phase 3 Trial to Evaluate the Efficacy and Safety of Aztreonam 75 mg Powder and Diluent for Nebuliser Solution (AZLI) versus Tobramycin Nebuliser Solution (TNS) in an Int...
    Medical condition: Adult and paediatric cystic fibrosis (CF) patients with pulmonary Pseudomonas aeruginosa (PA) infection.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011762 Cystic fibrosis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) ES (Completed) GB (Completed) IE (Completed) DK (Completed) DE (Completed) NL (Completed) IT (Completed) PT (Completed) AT (Completed) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 58  59  60  61  62  63  64  65  66 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 20 08:26:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA